Ipilimumab plus dacarbazine for previously untreated metastatic melanoma - Test2 - elhamkhani - TriplyDB

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

http://www.wikidata.org/entity/Q28131634

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma Melanoma: from melanocyte to genetic alterations and clinical options A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer Systemic treatments for metastatic cutaneous melanoma Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma State of the science: an update on renal cell carcinoma Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Toxicity management of immunotherapy for patients with metastatic melanoma Melanoma immunotherapy dominates the field Harnessing the immune system to improve cancer therapy Aptamers: A Feasible Technology in Cancer Immunotherapy Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now Uveal melanoma as a target for immune-therapy Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?Clinical utility of nivolumab in the treatment of advanced melanoma Cancer immunotherapy: the beginning of the end of cancer?Tremelimumab: research and clinical development The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines Novel targets in the treatment of advanced gastric cancer: a perspective review Advances in immunotherapy for melanoma Immunotherapy meets targeted therapy: will this team end the war against cancer?Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced Melanoma MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma Expanding the antimalarial toolkit: Targeting host-parasite interactions Medical management of malignant melanoma Current status of immunotherapy Advances in the treatment of newly diagnosed glioblastoma Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications Immune checkpoint inhibitors: therapeutic advances in melanoma Melanoma: oncogenic drivers and the immune system Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma

P2860

Q21131200-19A53CEA-6953-4B33-B859-9E957E371681 Q21245488-CE592A1B-759B-4815-B482-33A7BC7D165B Q21284811-2E9074CE-833F-449C-8CEF-01FA16701DC0 Q22001066-D3DFB941-8FF8-4C56-BB8A-FC8B4839575F Q24194804-6E10AE9F-DCE2-4F9C-9AAD-DC372A0A6167 Q24594790-B0AA7F48-5A94-4D40-B93B-87D1660D7F9E Q24629841-F4990170-178F-4BFD-882D-47581DFD78FD Q24630685-A3D6C129-DCF1-4C39-B4FC-748D6CBD0006 Q24633070-026F1DBA-C84A-40E5-90BF-72D6D5211822 Q26738662-BFF5E849-D550-429F-87E7-CC2929CD5B5C Q26738671-93FE3D2B-2DDE-4DF0-9856-D00A2C5CA4E0 Q26738698-8E4AC838-65A0-4269-9D21-B7F262C3375E Q26740303-910229E9-EAF6-4C10-9858-4561DB0F5509 Q26744758-894520E7-66F0-43CE-8353-B1BBEB4431A9 Q26745557-EA905A27-CBD7-4FEE-9AC6-C44C4673E065 Q26747519-5179C9B6-A7F7-417A-A8FD-8EB52A8C85C2 Q26751230-394A4C5D-E0F3-464E-AE56-FF76342D9D43 Q26751268-6A65A207-EEA9-4904-B5B3-F42D790D601C Q26752277-2022D50E-6D68-4FB4-B334-43987E5E2C1D Q26752822-5735C6F1-531C-4EB4-B92E-40A5364F7CF7 Q26764792-FAB5A809-FA02-4707-9DB4-E8EBA49D3F40 Q26765208-1F1D3E4F-7D10-4614-BC00-1D2AEE0D18BC Q26768558-D7B598E1-4E54-4566-ACB2-1954AC252F80 Q26769721-8D4DDC40-3E65-4493-8ADC-268A0D3066A8 Q26769884-8C54A5DC-427F-4EF6-BB09-6810133956F8 Q26770492-E519DFCB-36C1-4913-9022-6F1540F6224D Q26771119-1B342A6D-BEEF-453E-82E6-4C8D089497AF Q26771192-250A5A82-364F-4836-BBC7-F968B93BBAD1 Q26772015-E22B6889-FA8D-47F5-834B-0D97B9166663 Q26772866-9FA9342C-92D8-47DB-B69B-1E837F713937 Q26773302-BF65622A-E134-4ADA-B1DA-4DC1CDBEB1C5 Q26773314-F73560B1-3468-47B1-8B38-1F2D2E38B178 Q26773514-935640DD-4FC7-45B9-8766-DB1CCC3B7D65 Q26774669-5BAB8FEF-C51B-4C2C-8831-3A2EB64F06F5 Q26775034-434F2A79-066D-4433-88AF-E449F3D41C1C Q26775383-5C67F9D5-F35B-4ECD-8B5E-ACCB59C426EA Q26775546-23CC7A32-4A91-4170-9617-E2485F6DF344 Q26775591-5BC4E9A9-9F5F-4134-BC0C-12D7F35441CC Q26775598-820FB891-ABA1-41CB-B679-3811A276C34C Q26775769-CCA9B3E7-E4F3-4A5E-B8D1-22E22166CD10

P2860

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

http://www.wikidata.org/entity/Q28131634

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@ast

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@en

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@nl

type

label

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@ast

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@en

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@nl

altLabel

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

@en

prefLabel

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@ast

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@en

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@nl

P1433

Q28131634-27BEE4F1-C45E-4F9C-94D1-FB16249E6A7C

P1476

Q28131634-6FCDFC57-D08D-4A1C-86BD-8D1129DDFDB2

P2093

Q28131634-130151E4-038F-48C7-B911-E3DB4A763946

Q28131634-132D884A-BB8F-4B47-9344-B2E2D5531D7A

Q28131634-1AC16319-6981-4ED5-912B-EBEEC7DE25EE

Q28131634-1DDBC23E-FFD3-470C-865D-62EE9EAD7980

Q28131634-204A4E9F-E943-4C1D-A570-F882FE8E73B4

Q28131634-2240BB08-6A39-4BF7-B388-C598C8CCE36E

Q28131634-3C4B0317-4CB5-4D35-B777-4CA0464B6CB3

Q28131634-412544EF-F29D-4D2D-A97C-8A49DE5681D9

Q28131634-43B81ACE-D835-43AC-ABDC-01116AEAA2AD

Q28131634-66212D00-F5D0-476F-A663-4092AABA7B2E

P304

Q28131634-54CB401D-DDE8-4175-9214-40421ABFFD58

P31

Q28131634-62D579F9-C7F6-4F12-B088-1430168A06BD

P3181

Q28131634-252AFACB-2515-40BF-A925-AE2B4883C0C9

P356

Q28131634-3B815BC9-C913-464D-9453-438D7E598947

P407

Q28131634-D19974B2-1859-4EF6-86E6-ED6BA0FC19C0

P433

Q28131634-9AC9644B-4DA7-4192-AE00-2B62AE3294E3

P478

Q28131634-52CB9CB3-A715-48F3-9DDC-DFA1132CF186

P50

Q28131634-3C04C7F5-BF4C-49B9-9B3C-D91F211F0250

Q28131634-40C55440-93BC-4F33-B36F-833D5B68B0FD

Q28131634-4BA5C6AB-720C-4C3A-977C-69A398EBA589

Q28131634-544EC2B1-6E62-4BB6-AC1A-829999B353FA

Q28131634-7196FF1A-34D6-4E5C-AA79-21BC7FEC1A1F

P577

Q28131634-1A7CF7C6-94B7-453C-8611-06D877327DB9

P698

Q28131634-616DAB35-95D8-47AA-A860-A383CBFC727D

P921

Q28131634-74254D74-6627-4A9D-A017-79C05222BAD5

P3181

P356

P1433

The New England Journal of Medicine

P1476

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

@en

P2093

Alessandro Testori

http://www.w3.org/2001/XMLSchema#string

Axel Hauschild

http://www.w3.org/2001/XMLSchema#string

Axel Hoos

http://www.w3.org/2001/XMLSchema#string

Caroline Robert

http://www.w3.org/2001/XMLSchema#string

Celeste Lebbe

http://www.w3.org/2001/XMLSchema#string

Jean-François Baurain

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jeffrey Weber

http://www.w3.org/2001/XMLSchema#string

Jon Richards

http://www.w3.org/2001/XMLSchema#string

Kaan Harmankaya

http://www.w3.org/2001/XMLSchema#string

P304

2517-2526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

167304

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1104621

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Jacques Grob

Igor N. Bondarenko

P577

2011-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21639810

http://www.w3.org/2001/XMLSchema#string

P921